---
schema_version: "secwatch.filing_event.v1"
accession: "0001185185-23-000223"
form_type: "8-K"
ticker: "BHIC"
cik: "0001784440"
company_name: "BioScience Health Innovations, Inc."
filed_at: "2023-03-16T23:59:59+00:00"
generated_at: "2026-06-18T00:47:58.506029+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Nowtransit completes reverse merger with Best Labs; new CEO and board appointed

## Summary
- Nowtransit issued 34,371,100 shares (85.39% of outstanding) for 100% of Best Labs common stock.
- Darren Lopez appointed CEO and director; John Chymboryk appointed director; Justin Earl resigned as officer.
- Fiscal year changed from August 31 to December 31 to align with Best Labs.
- Company ceased being a shell company upon closing of the share exchange.

## SEC filing metadata
- accession: 0001185185-23-000223
- form_type: 8-K
- ticker: BHIC
- cik: 0001784440
- company_name: BioScience Health Innovations, Inc.
- filed_at: 2023-03-16T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.01, 3.02, 5.02, 5.03, 5.06, 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1784440/000118518523000223/0001185185-23-000223-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1784440/000118518523000223/nowtransit20230316_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001185185-23-000223
- JSON: https://secwatch.observer/filing/0001185185-23-000223.json
- Plain text: https://secwatch.observer/filing/0001185185-23-000223.txt

## Key facts
- Executive change
  Darren Lopez was appointed as Chief Executive Officer at BioScience Health Innovations, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: Darren López was appointed as the Chief Executive Officer of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1784440/000118518523000223/0001185185-23-000223-index.htm
- Executive change
  John Chymboryk was appointed as Director at BioScience Health Innovations, Inc..
  - Action: appointed
  - Role: Director
  source text: Darren Lopez and John Chymboryk were appointed to serve on the Board of Directors
  evidence_url: https://www.sec.gov/Archives/edgar/data/1784440/000118518523000223/0001185185-23-000223-index.htm
- Executive change
  Justin Earl resigned as Officer at BioScience Health Innovations, Inc..
  - Action: resigned
  - Role: Officer
  source text: Effective upon the Closing, Justin Earl tendered his resignation as the sole officer of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1784440/000118518523000223/0001185185-23-000223-index.htm
- Executive change
  Darren Lopez was appointed as Director at BioScience Health Innovations, Inc..
  - Action: appointed
  - Role: Director
  source text: Darren Lopez and John Chymboryk were appointed to serve on the Board of Directors
  evidence_url: https://www.sec.gov/Archives/edgar/data/1784440/000118518523000223/0001185185-23-000223-index.htm
- Governance Changes
  BioScience Health Innovations, Inc.: Company ceased being a shell company upon closing of the Exchange Agreement (effective 2023-03-10).
  - Change: shell status
  - Effective: 2023-03-10
  source text: As a result of the Closing of the Exchange Agreement, the Company ceased being a shell company, as that term is defined by Rule 12b-2 under the Securities Exchange Act of 1934.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1784440/000118518523000223/0001185185-23-000223-index.htm
- Governance Changes
  BioScience Health Innovations, Inc.: Changed fiscal year end from August 31 to December 31 (effective 2023-03-10).
  - Change: fiscal year change
  - Effective: 2023-03-10
  source text: Simultaneously with the Closing, the Company changed its fiscal year end from August 31 to December 31 as a result of the Exchange to conform its fiscal year end to that of Best.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1784440/000118518523000223/0001185185-23-000223-index.htm
- M&A Transactions
  BioScience Health Innovations, Inc. completed an acquisition involving Best Labs, Inc. and its shareholders (closed 2023-03-10).
  - Action: acquisition
  - Counterparty: Best Labs, Inc. and its shareholders
  - Closing: 2023-03-10
  source text: The transaction consummated on March 10, 2023 (the “Closing”). Upon the Closing, the Company issued the Best shareholders signatory 34,371,100 shares of the Company’s common stock, representing approximately 85.39% of the shares of the Company’s common stock to be outstanding, in exchange for all of the shares of Best common stock held by such Best shareholders (the “Exchange”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1784440/000118518523000223/0001185185-23-000223-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.